BR112017028550A2 - proteínas de fusão de fragmentos de proteína humana para criar composições de inmunoglobulina fc multimerizadas ordinárias com relação de complemento melhorado - Google Patents
proteínas de fusão de fragmentos de proteína humana para criar composições de inmunoglobulina fc multimerizadas ordinárias com relação de complemento melhoradoInfo
- Publication number
- BR112017028550A2 BR112017028550A2 BR112017028550A BR112017028550A BR112017028550A2 BR 112017028550 A2 BR112017028550 A2 BR 112017028550A2 BR 112017028550 A BR112017028550 A BR 112017028550A BR 112017028550 A BR112017028550 A BR 112017028550A BR 112017028550 A2 BR112017028550 A2 BR 112017028550A2
- Authority
- BR
- Brazil
- Prior art keywords
- fusion proteins
- multimerized
- human protein
- protein fragment
- enhanced complement
- Prior art date
Links
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 title abstract 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 102000003839 Human Proteins Human genes 0.000 title 1
- 108090000144 Human Proteins Proteins 0.000 title 1
- 230000000295 complement effect Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
Abstract
a presente invenção refere-se a uma série de formas multimerizadas totalmente recombinantes de imunoglobulina fc que apresentam assim a imunoglobulina fc polivalente a receptores de células imunes. as proteínas de fusão existem como frações homônimas e altamente ordenadas multiméricas, denominadas stradomers. a invenção refere-se a stradomers que aumentam a multimerização e se ligam preferencialmente para complementar e que são úteis no tratamento e prevenção de doenças.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562196478P | 2015-07-24 | 2015-07-24 | |
PCT/US2016/043746 WO2017019565A2 (en) | 2015-07-24 | 2016-07-22 | Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017028550A2 true BR112017028550A2 (pt) | 2018-09-04 |
Family
ID=57885189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017028550A BR112017028550A2 (pt) | 2015-07-24 | 2016-07-22 | proteínas de fusão de fragmentos de proteína humana para criar composições de inmunoglobulina fc multimerizadas ordinárias com relação de complemento melhorado |
Country Status (23)
Country | Link |
---|---|
US (1) | US20180244772A1 (pt) |
EP (2) | EP3828204A1 (pt) |
JP (2) | JP6937737B2 (pt) |
KR (2) | KR102649702B1 (pt) |
CN (2) | CN116063510A (pt) |
AU (2) | AU2016297862C1 (pt) |
BR (1) | BR112017028550A2 (pt) |
CA (1) | CA2991254A1 (pt) |
CY (1) | CY1123719T1 (pt) |
DK (1) | DK3325011T6 (pt) |
ES (1) | ES2846024T7 (pt) |
FI (1) | FI3325011T6 (pt) |
HK (1) | HK1254447A1 (pt) |
HU (1) | HUE053062T2 (pt) |
IL (2) | IL256879B1 (pt) |
LT (1) | LT3325011T (pt) |
MX (2) | MX2018000587A (pt) |
PL (1) | PL3325011T6 (pt) |
PT (1) | PT3325011T (pt) |
RU (2) | RU2020138007A (pt) |
SI (1) | SI3325011T1 (pt) |
TW (2) | TWI729993B (pt) |
WO (1) | WO2017019565A2 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3464347B1 (en) | 2016-06-07 | 2023-05-31 | Gliknik Inc. | Cysteine-optimized stradomers |
EP3487534A4 (en) | 2016-07-22 | 2020-03-25 | Gliknik Inc. | FUSION PROTEINS FROM HUMAN PROTEIN FRAGMENTS FOR THE PRODUCTION OF MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH INCREASED FC RECEPTOR BINDING |
KR20190095929A (ko) | 2016-12-09 | 2019-08-16 | 글리크닉 인코포레이티드 | 다합체화 스트라도머인 gl-2045의 제조 최적화 |
WO2018107082A1 (en) | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Methods of treating inflammatory disorders with multivalent fc compounds |
CN112004550A (zh) | 2017-12-14 | 2020-11-27 | 康诺贝林伦瑙有限公司 | 用于治疗视神经脊髓炎的重组IgG Fc多聚体 |
JP2022547692A (ja) | 2019-09-13 | 2022-11-15 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 免疫複合体介在性腎臓障害の処置のための組み換えIgG Fc多量体 |
US20230122067A1 (en) * | 2020-03-26 | 2023-04-20 | Denka Company Limited | REAGENT COMPRISING ANTIBODY FROM WHICH PART OF Fc REGION IS DELETED |
CN114478741B (zh) * | 2021-12-31 | 2023-03-07 | 苏州大学 | contactin 6蛋白突变体及其编码基因、表达载体与应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007089A1 (en) * | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
ES2109362T3 (es) | 1991-06-21 | 1998-01-16 | Univ Cincinnati | Unas proteinas administrables oralmente y metodo para hacerlas. |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
US20150071948A1 (en) * | 2003-09-26 | 2015-03-12 | Gregory Alan Lazar | Novel immunoglobulin variants |
EP2087111A2 (en) * | 2007-03-19 | 2009-08-12 | Medimmune Limited | Polypeptide variants |
EP2641913B1 (en) * | 2007-06-01 | 2018-04-18 | University of Maryland, Baltimore | Immunoglobulin constant region Fc receptor binding agents |
US8362210B2 (en) * | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
TWI588157B (zh) * | 2010-07-28 | 2017-06-21 | 吉林尼克公司 | 產生依序多聚體化免疫球蛋白fc組合物之天然人類蛋白質片段之融合蛋白 |
JP6167040B2 (ja) * | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
MX347077B (es) * | 2010-12-23 | 2017-04-10 | Janssen Biotech Inc | Mutantes fc de anticuerpos resistentes a proteasas activas. |
EA201400993A1 (ru) * | 2012-03-08 | 2015-05-29 | Галозим, Инк. | Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения |
MX2015002269A (es) * | 2012-08-20 | 2015-07-06 | Gliknik Inc | Moleculas con actividad de union al antigeno y al receptor fc gamma polivalente. |
US9714291B2 (en) * | 2012-10-05 | 2017-07-25 | Kyowa Hakko Kirin Co., Ltd | Heterodimer protein composition |
AU2015226100B2 (en) | 2014-03-05 | 2020-05-07 | UCB Biopharma SRL | Multimeric Fc proteins |
-
2016
- 2016-07-22 RU RU2020138007A patent/RU2020138007A/ru unknown
- 2016-07-22 KR KR1020187001187A patent/KR102649702B1/ko active IP Right Grant
- 2016-07-22 FI FIEP16831166.0T patent/FI3325011T6/fi active
- 2016-07-22 PT PT168311660T patent/PT3325011T/pt unknown
- 2016-07-22 ES ES16831166T patent/ES2846024T7/es active Active
- 2016-07-22 CA CA2991254A patent/CA2991254A1/en active Pending
- 2016-07-22 DK DK16831166.0T patent/DK3325011T6/da active
- 2016-07-22 JP JP2018501267A patent/JP6937737B2/ja active Active
- 2016-07-22 BR BR112017028550A patent/BR112017028550A2/pt active Search and Examination
- 2016-07-22 CN CN202211181358.XA patent/CN116063510A/zh active Pending
- 2016-07-22 WO PCT/US2016/043746 patent/WO2017019565A2/en active Application Filing
- 2016-07-22 RU RU2018106332A patent/RU2737378C2/ru active
- 2016-07-22 IL IL256879A patent/IL256879B1/en unknown
- 2016-07-22 KR KR1020247008871A patent/KR20240042137A/ko active Search and Examination
- 2016-07-22 EP EP20207511.5A patent/EP3828204A1/en active Pending
- 2016-07-22 LT LTEP16831166.0T patent/LT3325011T/lt unknown
- 2016-07-22 HU HUE16831166A patent/HUE053062T2/hu unknown
- 2016-07-22 MX MX2018000587A patent/MX2018000587A/es unknown
- 2016-07-22 EP EP16831166.0A patent/EP3325011B3/en active Active
- 2016-07-22 IL IL309260A patent/IL309260A/en unknown
- 2016-07-22 CN CN201680042311.1A patent/CN107847599B/zh active Active
- 2016-07-22 PL PL16831166.0T patent/PL3325011T6/pl unknown
- 2016-07-22 SI SI201631063T patent/SI3325011T1/sl unknown
- 2016-07-22 AU AU2016297862A patent/AU2016297862C1/en active Active
- 2016-07-25 TW TW105123519A patent/TWI729993B/zh active
- 2016-07-25 TW TW110118740A patent/TWI812951B/zh active
-
2018
- 2018-01-15 MX MX2022008337A patent/MX2022008337A/es unknown
- 2018-01-24 US US15/878,509 patent/US20180244772A1/en active Pending
- 2018-10-23 HK HK18113532.8A patent/HK1254447A1/zh unknown
-
2021
- 2021-01-13 CY CY20211100019T patent/CY1123719T1/el unknown
- 2021-06-25 JP JP2021106156A patent/JP7122440B2/ja active Active
-
2022
- 2022-08-31 AU AU2022224791A patent/AU2022224791A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017028550A2 (pt) | proteínas de fusão de fragmentos de proteína humana para criar composições de inmunoglobulina fc multimerizadas ordinárias com relação de complemento melhorado | |
CO2018009995A2 (es) | Proteínas de unión y métodos de uso de las mismas | |
EA201791057A1 (ru) | Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf | |
CO2017000506A2 (es) | Receptor quimérico de antígeno cll-1 | |
BR112016014810A2 (pt) | Antagonistas de fcrn e métodos de uso | |
GEP201706794B (en) | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof | |
PE20240111A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
BR112013002074A2 (pt) | proteínas de fusão de fragmentos de proteína humana natural para criar composições de fc de imunoglobulina multimerizada ordenadamente | |
CR20140029A (es) | Proteínas de unión a antígeno de tnf-alfa con unión a fcrn incrementada | |
UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
EA201692394A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
BR112015022208A8 (pt) | proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo | |
CO2019003951A2 (es) | Proteínas de unión a cd123 y composiciones y métodos relacionados | |
SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
AR101753A1 (es) | COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO | |
EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
MX2023000738A (es) | Proteinas de union a antigeno que activan el receptor de leptina. | |
EA201892063A1 (ru) | МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn | |
WO2017006052A3 (fr) | UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE | |
BR112017002703A2 (pt) | anticorpos específicos de mmp9. | |
BR112019001156A2 (pt) | proteínas de fusão de fragmentos de proteína humana para criar composições de fc de imunoglobulina multimerizadas ordenadas com ligação de receptor fc reforçada | |
AR106198A1 (es) | Anticuerpos biespecíficos para la proteína de muerte celular programada 1 (pd1) y para la proteína humana que pertenece a la superfamilia de las inmunoglobulinas (tim3) | |
EA202090582A3 (ru) | Полипептиды il-22, химерные белки il-22 fc и их применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |